Olutasidenib
Sources
publication, as of 2026-11-07
https://pmc.ncbi.nlm.nih.gov/articles/PMC9825299/
de la Fuente MI et al. Olutasidenib (FT-2102) in IDH1-mutant relapsed or refractory glioma. Neuro-Oncology 2023;25:146-156. PMC9825299 (NCT03684811)
Brief source I10
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03684811
A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06161974
Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
ClinicalTrials.gov API v2 record, retrieved 2026-11-07